Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 28107

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Diagnostic
  • Disease
  • Therapeutic
  • Imaging
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28107

License Grant
The Licensor has licensed the exclusive worldwide rights for the treatment of non-cancer indications to one of our most advanced therapeutic compounds, epratuzumab to the Belgium Licensee. The Licensee is granted the right to sublicense epratuzumab, subject to obtaining the Licensor's prior consent, to a third party for the United States and certain other territories, according to the Amendment Agreement.
License Property
Epratuzumab is a humanized monoclonal antibody targeting CD22 receptors on B lymphocytes. It is being evaluated for the treatment of non-Hodgkin’s lymphoma, and for autoimmune diseases such as systemic lupus erythematosus (SLE). The U.S. Food and Drug Administration has granted Epratuzumab Fast Track Product designation for the treatment of patients with lupus.
Field of Use
Epratuzumab has been licensed for all autoimmune disease indications worldwide to the biopharmaceutical manufacturing company.

IPSCIO Record ID: 3285

License Grant
Licensor grants exclusive rights to develop, commercialize and market Rituxan outside the United States and Canada.
License Property
Rituximabis a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Field of Use
RITUXAN® (Rituximab) is indicated for the treatment of:
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy

IPSCIO Record ID: 46309

License Grant
The Company entered into an Exclusive License Agreement with Licensee for U.S. and Canadian rights to the Company's bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. This license agreement is for BENDEKAâ„¢.
License Property
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL for treatment of patients with chronic lymphocytic leukemia, ('CLL') and patients with non-Hodgkin's lymphoma ('NHL').
Field of Use
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

IPSCIO Record ID: 239007

License Grant
Licensor grants an exclusive license, with the right to sublicense, under Licensed Patent Rights, Licensed Trademark Rights and Licensed Know-How, to make, have made, use, sell, lease, offer to sell or lease, import, export within the Territory, or otherwise exploit, or transfer physical possession of or title in, Product(s) in the Field in the Territory.

Licensor grants a non-exclusive, irrevocable, perpetual, unrestricted worldwide right and license, without the right to sublicense, to make, have made, and use Licensed Know-How, for Licensees internal research and development purposes only.

Licensor grants a right of first negotiation and a right of first refusal to all Antibodies which bind to CD22 and to which a radiolabel is further attached, including, but not limited to, 90Y-Epratuzumab and 186Re-Epratuzumab; which are owned or controlled by Licensor on the Closing Date or during the term of this Agreement, collectively, the Radiolabeled Product(s)).

Licensor shall grant an exclusive first negotiating period of ninety (90) days to agree upon the terms and conditions of a separate licensing agreement for the development and commercialization of such Radiolabeled Product in the Field in the Territory.

License Property
Product(s) shall mean the following products which are owned or controlled by Licensor or Licensee:
(a) Epratuzumab and (b) any 2nd Generation Product for which Licensee provides notification to Licensor. In the event Licensee provides notification, the Antibody which is the subject of such notification shall be included within the definition of Product(s), subject to the terms and conditions of this Agreement (including for use solely in the Territory) relative to 2nd Generation Product(s) which may be included within the definition of Product(s).

The Radiolabeled Product(s)) are all Antibodies which bind to CD22 and to which a radiolabel is further attached, including, but not limited to, 90Y-Epratuzumab and 186Re-Epratuzumab; which are owned or controlled by Licensee on the Closing Date or during the term of this Agreement.

Licensed Trademark Rights shall mean any generic name (USAN/INN), trade name, logo or trademark (whether or not registered) in any country within the Territory owned (in whole or part) or controlled by Licensor as of the Closing Date –  including LymphoCide.

Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).

Field of Use
Field shall mean all human therapeutic, prophylactic, palliative and in vitro diagnostic uses, only to support Product(s), but excluding in vivo diagnostic imaging uses with Lymphoscan as well as other imaging agents.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.